A comparator trial of BPX-501 in malignant and nonmalignant pediatric patients receiving a matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jul 2019 According to a Bellicum Pharmaceuticals media release, this trial will be conducted at same time period and at the similar treatment centres where the BP-004 rivo-cel study was conducted.
08 Jul 2019 Results published in the Bellicum Pharmaceuticals Media Release.
27 Nov 2018 According to a Bellicum Pharmaceuticals media release, data from this study will be presented at the 60th American Society of Hematology (ASH) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com